124 related articles for article (PubMed ID: 10692785)
1. [Staging and therapeutic options in local prostatic carcinoma].
Stoffel F; Forster T; Gasser TC
Ann Ital Chir; 1999; 70(5):665-70. PubMed ID: 10692785
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic options in locally defined or advanced prostate cancer.
Altwein JE
Eur Urol; 1999; 35 Suppl 1():9-15; discussion 16. PubMed ID: 10081697
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Options in Locally Defined or Advanced Prostate Cancer.
Altwein JE
Eur Urol; 1998 Dec; 35 Suppl S1():9-16. PubMed ID: 9858847
[TBL] [Abstract][Full Text] [Related]
4. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
5. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
6. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0.
Tilly W; Gellermann J; Graf R; Hildebrandt B; Weissbach L; Budach V; Felix R; Wust P
Strahlenther Onkol; 2005 Jan; 181(1):35-41. PubMed ID: 15660191
[TBL] [Abstract][Full Text] [Related]
7. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Zincke H; Lau W; Bergstralh E; Blute ML
J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
[TBL] [Abstract][Full Text] [Related]
8. [The treatment options for localized prostate cancer].
Livne PM
Harefuah; 2006 Jan; 145(1):36-7, 77. PubMed ID: 16450723
[TBL] [Abstract][Full Text] [Related]
9. Management of prostate cancer in China: a multicenter report of 6 institutions.
Peyromaure M; Debré B; Mao K; Zhang G; Wang Y; Sun Z; Xu D; Jiang J; Sun Y
J Urol; 2005 Nov; 174(5):1794-7. PubMed ID: 16217289
[TBL] [Abstract][Full Text] [Related]
10. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
11. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
[TBL] [Abstract][Full Text] [Related]
12. Local-regional prostate cancer.
Jones MJ; Koeneman KS
Urol Oncol; 2008; 26(5):516-21. PubMed ID: 18774466
[TBL] [Abstract][Full Text] [Related]
13. Cancer of the prostate.
Bracarda S; de Cobelli O; Greco C; Prayer-Galetti T; Valdagni R; Gatta G; de Braud F; Bartsch G
Crit Rev Oncol Hematol; 2005 Dec; 56(3):379-96. PubMed ID: 16310371
[TBL] [Abstract][Full Text] [Related]
14. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Zietman AL; Thakral H; Wilson L; Schellhammer P
J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
18. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
19. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease].
Heidenreich A; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Mottet N; Schmid HP; van der Kwast T; Wiegel T; Zattoni F
Actas Urol Esp; 2011 Oct; 35(9):501-14. PubMed ID: 21757259
[TBL] [Abstract][Full Text] [Related]
20. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]